The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection

G. McCaughey, D. F. Gilpin, J. S. Elborn, Michael M. Tunney*

*Corresponding author for this work

Research output: Contribution to journalLiterature review

10 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is characterised by chronic polymicrobial airway infection and inflammation, which is the major cause of morbidity and mortality. Aggressive use of antimicrobials has been fundamental in increasing the life expectancy of CF patients in recent years. However, enhanced culture and non-culture based detection methods have identified bacteria in the CF lung not previously isolated from CF patients by routine diagnostic microbiology Coupled with increasing antimicrobial resistance, the future of antimicrobial therapy in CF respiratory infection remains challenging. New strategies are needed to address these problems and ensure improvements in life expectancy are maintained. Potential future strategies include the use of new antimicrobial agents and formulations currently in clinical trials, alternative methods of selecting appropriate therapeutic regimens, determination of the pathogenicity of species newly associated with CF and the development of new antimicrobials and adjuvants for use in clinical practice.

Original languageEnglish
Pages (from-to)385-396
Number of pages12
JournalExpert review of respiratory medicine
Volume7
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Microbial Drug Resistance
Cystic Fibrosis
Infection
Life Expectancy
Therapeutics
Anti-Infective Agents
Microbiology
Coinfection
Respiratory Tract Infections
Virulence
Clinical Trials
Inflammation
Morbidity
Bacteria
Lung
Mortality

Cite this

@article{bee896c25bc9443f9e81cf1aad6727e2,
title = "The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection",
abstract = "Cystic fibrosis (CF) is characterised by chronic polymicrobial airway infection and inflammation, which is the major cause of morbidity and mortality. Aggressive use of antimicrobials has been fundamental in increasing the life expectancy of CF patients in recent years. However, enhanced culture and non-culture based detection methods have identified bacteria in the CF lung not previously isolated from CF patients by routine diagnostic microbiology Coupled with increasing antimicrobial resistance, the future of antimicrobial therapy in CF respiratory infection remains challenging. New strategies are needed to address these problems and ensure improvements in life expectancy are maintained. Potential future strategies include the use of new antimicrobial agents and formulations currently in clinical trials, alternative methods of selecting appropriate therapeutic regimens, determination of the pathogenicity of species newly associated with CF and the development of new antimicrobials and adjuvants for use in clinical practice.",
author = "G. McCaughey and Gilpin, {D. F.} and Elborn, {J. S.} and Tunney, {Michael M.}",
year = "2013",
month = "8",
doi = "10.1586/17476348.2013.814411",
language = "English",
volume = "7",
pages = "385--396",
journal = "Expert review of respiratory medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection

AU - McCaughey, G.

AU - Gilpin, D. F.

AU - Elborn, J. S.

AU - Tunney, Michael M.

PY - 2013/8

Y1 - 2013/8

N2 - Cystic fibrosis (CF) is characterised by chronic polymicrobial airway infection and inflammation, which is the major cause of morbidity and mortality. Aggressive use of antimicrobials has been fundamental in increasing the life expectancy of CF patients in recent years. However, enhanced culture and non-culture based detection methods have identified bacteria in the CF lung not previously isolated from CF patients by routine diagnostic microbiology Coupled with increasing antimicrobial resistance, the future of antimicrobial therapy in CF respiratory infection remains challenging. New strategies are needed to address these problems and ensure improvements in life expectancy are maintained. Potential future strategies include the use of new antimicrobial agents and formulations currently in clinical trials, alternative methods of selecting appropriate therapeutic regimens, determination of the pathogenicity of species newly associated with CF and the development of new antimicrobials and adjuvants for use in clinical practice.

AB - Cystic fibrosis (CF) is characterised by chronic polymicrobial airway infection and inflammation, which is the major cause of morbidity and mortality. Aggressive use of antimicrobials has been fundamental in increasing the life expectancy of CF patients in recent years. However, enhanced culture and non-culture based detection methods have identified bacteria in the CF lung not previously isolated from CF patients by routine diagnostic microbiology Coupled with increasing antimicrobial resistance, the future of antimicrobial therapy in CF respiratory infection remains challenging. New strategies are needed to address these problems and ensure improvements in life expectancy are maintained. Potential future strategies include the use of new antimicrobial agents and formulations currently in clinical trials, alternative methods of selecting appropriate therapeutic regimens, determination of the pathogenicity of species newly associated with CF and the development of new antimicrobials and adjuvants for use in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84887728119&partnerID=8YFLogxK

U2 - 10.1586/17476348.2013.814411

DO - 10.1586/17476348.2013.814411

M3 - Literature review

C2 - 23964628

VL - 7

SP - 385

EP - 396

JO - Expert review of respiratory medicine

JF - Expert review of respiratory medicine

SN - 1747-6348

IS - 4

ER -